Piper Sandler analyst Edward Tenthoff keeps his Overweight rating and $32 price target on Moderna, saying the company's "Manufacturing & Digital Day" presentation showcased its "overwhelming advantages" in mRNA drug discovery, development, and manufacturing, with ability to produce over 75g batches at a cost that is 69% lower than last year. The analyst notes that this capability has allowed Moderna to manufacture CMV vaccine mRNA-1647 in its ongoing phase 2 study and also gives it the speed to ship coronavirus vaccine mRNA-1273 for clinical testing in just 42 days.
Stock futures saw modest early gains following Wednesday's mixed action and Thursday's holiday closure as investors returned for a shortened Black Friday session. The Nasdaq was... To see the rest of the story go to thefly.com. See Story Here